Diabetic Macular Edema: Protecting Your Central Vision
Understanding Diabetic Macular Edema
DME is a condition in which fluid builds up in the macula, causing it to swell and disrupting central vision. It develops as a result of diabetes-related damage to the blood vessels inside the eye, and it can affect people with either type 1 or type 2 diabetes.
The macula is a small but essential area at the center of the retina, which is the light-sensitive tissue lining the back of the eye. The macula is responsible for the sharp central vision needed for reading, driving, recognizing faces, and seeing fine detail. When the macula swells with fluid, these everyday tasks become difficult or impossible.
Over time, high blood sugar levels weaken the walls of the small blood vessels throughout the retina. This weakening disrupts the blood-retinal barrier, a protective layer that normally prevents fluid from leaking into retinal tissue. When the barrier breaks down, fluid and proteins seep into the surrounding tissue and cause swelling.
The process often begins with the retina not receiving enough oxygen, a condition called retinal hypoxia. In response, the body increases production of a protein called vascular endothelial growth factor (VEGF). VEGF signals the growth of new, fragile blood vessels that leak easily and worsen fluid buildup in the macula.
Diabetic retinopathy is the broader term for diabetes-related damage to the retinal blood vessels. DME is a specific complication that can develop at any stage of diabetic retinopathy, whether early or advanced. Not everyone with diabetic retinopathy will develop DME, but the risk increases as retinopathy becomes more severe.
Who Is at Risk for DME
Several factors influence a person's likelihood of developing DME. Some are related to how long they have lived with diabetes, and others involve overall health conditions that affect the blood vessels throughout the body.
The longer a person has diabetes, the greater the chance of developing DME. Long-term exposure to elevated blood sugar gradually damages the delicate blood vessels inside the eye. This is why ongoing monitoring becomes increasingly important as the years pass, even when vision feels unchanged.
Poor blood sugar control is one of the strongest risk factors for DME. A glycated hemoglobin (HbA1c) reading, which reflects average blood sugar over the past two to three months, above the target recommended by a physician is associated with greater risk of retinal blood vessel damage. Keeping blood sugar as stable as possible significantly reduces that risk.
High blood pressure and elevated cholesterol levels both contribute to damage in the small blood vessels of the retina. When these conditions are not well managed, they increase the likelihood that fluid will leak into the macula. Treating blood pressure and cholesterol effectively, alongside blood sugar control, helps protect retinal health.
Several other factors can further raise the risk of developing DME. Being aware of these helps patients and their care teams prioritize closer monitoring.
- Presence and increasing severity of diabetic retinopathy
- Diabetic kidney disease (nephropathy), which signals widespread blood vessel damage throughout the body
- Pregnancy in women with diabetes, which can temporarily worsen retinopathy and macular swelling
- Ethnicity, with higher rates observed in Hispanic and African American populations
Signs and Symptoms of DME
DME does not always cause noticeable symptoms in its earliest stages, which makes routine eye exams essential for anyone living with diabetes. As the condition progresses, central vision becomes increasingly affected.
In the beginning, the amount of fluid leaking into the macula may be too small to cause any visible change in sight. Vision can appear completely normal even while the condition is advancing. This is one of the most important reasons why regular dilated eye exams are recommended for all people with diabetes, not just those who notice a problem.
As DME progresses, it affects the ability to see clearly in the center of the visual field. The following changes are common as swelling increases.
- Blurred or distorted central vision
- Difficulty reading or seeing fine print
- Problems recognizing faces
- Colors appearing washed out or faded
- Dark or empty areas in the center of the visual field
These changes may affect one or both eyes. Without treatment, ongoing fluid buildup can cause permanent damage to the macula and lasting vision loss. Any new or worsening change in vision should be evaluated promptly.
The sooner DME is identified, the more treatment options are available and the better the chances of preserving vision. Waiting until symptoms become severe means that some damage may already be difficult to reverse. Routine screening gives our specialists the opportunity to intervene at the earliest, most treatable stage.
How DME Is Diagnosed
Diagnosing DME involves a combination of imaging, examination, and testing. Our specialists use a full range of diagnostic tools to assess the extent of macular swelling and plan the most effective treatment.
The evaluation begins with a comprehensive dilated eye exam. Special drops widen the pupil so the specialist can view the retina and macula in detail. This exam reveals signs of fluid buildup, blood vessel damage, and other changes associated with diabetic retinopathy and DME.
Optical coherence tomography (OCT) is a noninvasive imaging test that creates detailed, cross-sectional pictures of the retina. It allows the specialist to measure the thickness of the macula and detect even small amounts of fluid. OCT is one of the most valuable tools for both diagnosing DME and tracking how well treatment is working over time.
In fluorescein angiography, a special dye is injected into a vein in the arm. As the dye moves through the retinal blood vessels, a camera captures images showing where leakage is occurring. This test helps identify damaged blood vessels and guides decisions about which areas of the retina need treatment.
A standard visual acuity test measures how clearly you can see at various distances. While it cannot diagnose DME on its own, it helps the specialist understand how much central vision has been affected. It also provides an important baseline for measuring changes after treatment begins.
Treatment Options for Diabetic Macular Edema
Several effective treatments are available for DME, and the right approach depends on the severity of swelling, how the eye responds, and individual health factors. Our specialists develop personalized treatment plans using the most current therapies available.
Anti-VEGF injections are currently the first-line treatment for DME. These medications are injected directly into the eye, a procedure called an intravitreal injection, to block the VEGF protein that promotes leaky blood vessel growth. By reducing VEGF activity, these injections decrease swelling in the macula and can improve or stabilize vision.
Several anti-VEGF medications are approved for the treatment of DME. Lucentis (ranibizumab) is typically given every four weeks. Eylea (aflibercept) may be given every four to eight weeks after an initial series of doses. Vabysmo (faricimab) targets both VEGF-A and a second pathway called Ang-2, and may be given as infrequently as every 16 weeks in appropriate patients. Avastin (bevacizumab) is used off-label for DME and is typically administered every four to six weeks.
Eylea HD, a high-dose form of aflibercept, offers the possibility of extended dosing intervals for patients who respond well to treatment. After one year of therapy, dosing may be extended to as long as every 20 weeks, reducing the number of injections and office visits required while maintaining the benefits of anti-VEGF therapy.
For some patients, inflammation plays a larger role in DME, and corticosteroid therapy may be more effective than anti-VEGF injections alone. Ozurdex (dexamethasone implant) is a biodegradable implant placed inside the eye that releases medication over several months. Iluvien (fluocinolone acetonide implant) provides sustained steroid therapy for up to three years. A specialist may recommend these options when anti-VEGF therapy has not produced adequate results.
Laser photocoagulation uses a focused beam of light applied to the retina to seal leaking blood vessels and reduce fluid accumulation. While anti-VEGF injections have largely replaced laser as the primary treatment for DME, laser therapy may still be used in combination with injections in certain situations where injections alone are not sufficient.
Susvimo (ranibizumab injection) is a surgically implanted device that continuously delivers anti-VEGF medication into the eye over time. It is designed for patients who have already responded well to intravitreal anti-VEGF injections. The device is refilled in the office by a specialist, reducing the need for frequent individual injections.
What to Expect During Treatment
Starting treatment for DME involves a series of visits and procedures that become more routine over time. Knowing what to expect can help patients feel more prepared and comfortable throughout the process.
Intravitreal injections are performed in the office and typically take only a few minutes. The eye is numbed with anesthetic drops before the injection, so most patients feel brief pressure or mild discomfort rather than sharp pain. Some redness, mild soreness, or temporary floaters may occur afterward, and these effects usually resolve within a few days.
DME treatment often requires a series of injections, especially during the first year. Most plans begin with monthly injections for the first several months, called a loading phase, to establish control over the swelling. After that, intervals between injections are adjusted based on how the eye responds. OCT imaging and visual acuity tests at each visit guide these decisions.
Regular follow-up is essential because DME can return if treatment is reduced too quickly. Keeping all scheduled appointments protects the progress made during treatment.
Anti-VEGF treatment can stabilize vision in most patients and improve vision in many. However, results depend on how long DME has been present, the degree of swelling, and how well blood sugar is managed. Some patients experience meaningful visual improvement, while others may achieve stabilization that prevents further decline. Complete restoration of vision is not typical, but significant gains are possible with consistent treatment.
Living With Diabetic Macular Edema
Managing DME extends beyond the eye clinic. Lifestyle habits, daily adjustments, and emotional well-being all play a role in long-term outcomes and quality of life.
Controlling blood sugar is one of the most important steps a person can take to slow the progression of DME. Working with a primary care physician or endocrinologist to keep HbA1c at or below the target level reduces ongoing damage to retinal blood vessels. Managing blood pressure and cholesterol through medication, diet, and exercise also supports long-term retinal health.
If DME has affected central vision, certain adjustments can help maintain independence and quality of life. Large-print materials, magnifying devices, improved lighting, and high-contrast display settings on phones and computers can make daily tasks more manageable. A low vision specialist can provide personalized recommendations based on the level of vision remaining.
Living with a condition that affects vision can bring stress, frustration, and anxiety. These feelings are understandable and common. Support groups for people with diabetic eye disease, counseling services, and open conversations with your care team can all be helpful. Staying well-informed about your condition and treatment plan often provides a greater sense of control and confidence.
Even when DME is well managed, ongoing monitoring is necessary. Fluid can return months or years after treatment ends, and new areas of leakage may develop over time. People with diabetes should have at least one dilated eye exam per year, and more frequent visits are recommended when DME or diabetic retinopathy has been diagnosed. Consistency with follow-up appointments is one of the most effective ways to protect remaining vision.
When to See a Specialist
Knowing when to seek evaluation, and when to act urgently, is an important part of managing eye health with diabetes. Routine care and prompt attention to warning signs together offer the best protection.
Every person with type 1 or type 2 diabetes should have regular dilated eye exams regardless of whether vision problems are present. The American Academy of Ophthalmology recommends that people with type 2 diabetes receive an eye exam at the time of diagnosis. People with type 1 diabetes should have their first exam within five years of diagnosis. These screenings allow specialists to detect and treat changes before vision is significantly affected.
Certain symptoms require immediate evaluation and should not be waited on. Seek care right away if you experience any of the following.
- A sudden increase in floaters (spots or shapes drifting across your vision)
- Flashes of light in one or both eyes
- A shadow, curtain, or dark area spreading across your vision
- Sudden vision loss in one eye
These symptoms may indicate a serious retinal complication that requires urgent treatment. Do not wait for a routine appointment if these occur.
If vision continues to decline despite ongoing treatment, it is important to talk openly with your specialist about alternatives. Switching between different anti-VEGF agents, adding corticosteroid therapy, combining treatments, or adjusting dosing intervals may produce better results. An honest conversation about how your eye is responding is essential to finding an approach that works for you.
Frequently Asked Questions
These answers address common questions about living with and managing DME, including details that may not be covered during a typical office visit.
In many cases, treatment significantly reduces macular swelling and can improve vision meaningfully. However, DME is typically managed as an ongoing condition rather than permanently eliminated. If fluid has been present in the macula for an extended period, some structural changes may be difficult to fully reverse. Starting treatment early and maintaining it consistently offers the best opportunity for vision improvement.
The total number of injections varies considerably from person to person and changes over time. Most plans begin with monthly injections during a loading phase, then shift to longer intervals based on how the eye responds. Some patients require ongoing injections for several years, while others eventually reach a point where the condition can be monitored without active treatment. Your specialist will adjust the plan based on OCT imaging and visual acuity results at each visit.
Yes, blood sugar management remains important even after DME has been diagnosed. While it may not resolve existing swelling on its own, keeping HbA1c at a stable, healthy level reduces further damage to retinal blood vessels and supports the effectiveness of eye treatments. Patients who maintain consistent blood sugar control over time often experience fewer recurrences of macular fluid and better long-term outcomes.
Diabetic retinopathy refers to the broader category of damage that diabetes causes to blood vessels throughout the retina. Diabetic macular edema is a specific complication of that damage in which fluid leaks into the macula and disrupts central vision. It is possible to have diabetic retinopathy without DME, but DME always occurs in the context of underlying retinopathy. Both conditions may require separate monitoring and treatment approaches.
Anti-VEGF injections have been used to treat retinal conditions for a significant number of years and have a well-studied safety record. As with any intraocular procedure, there are small risks including infection, bleeding, and temporary changes in eye pressure. Serious complications are rare. Your specialist monitors for these at every visit and will discuss any concerns about continued therapy. For most patients with DME, the benefit of preventing progressive vision loss clearly outweighs the risks of ongoing treatment.
Most patients can resume normal activities after intravitreal injections within a day or two. Temporary blurring or the presence of floaters immediately after an injection may make it advisable to avoid driving on the day of the procedure. If DME has affected central vision more significantly, your specialist can advise you on any necessary restrictions and connect you with low vision support services if needed. It is always best to discuss your specific situation with your care team before making decisions about driving or safety-sensitive tasks.
Schedule Your Eye Exam at EyeCare Consultants of NJ
If you have diabetes, early and consistent eye care is one of the most effective steps you can take to protect your vision for the long term. Our team at EyeCare Consultants of NJ is experienced in evaluating and treating diabetic eye conditions, including DME, using the most current diagnostic tools and therapies available. We welcome patients from across New Jersey at our Edison and Woodland Park locations and are committed to delivering the thorough, personalized care you deserve.
Dr. Arnett is very kind
Shirly
Friendly and caring retina surgeon, I highly recommend Dr. Arnett.
Shirly
It was my first visit. Doctor Kayserman was very understanding of the problem. I have to have surgery. I'm hoping for 🙏
Boris
Dr. Arnett deserves 10 stars. He is the best.
AJ
Dr. Kayserman was gentle, efficient and provided extremely valuable information which was comforting to me. I felt better after seeing her and am looking forward to additional visits.
Lina N.